Newcleo plc · NASDAQ:NWCL
Newcleo — SPAC Merger (August 2026)
23 slides from Newcleo's SPAC merger presentation, Aug 26, 2026
Slide 1: newcleo General Meeting
Private and Confidential newcleo General Meeting
Slide 2: Disclaimer
Disclaimer ‘This prsentn (he “Presentation has ban prepared by newtlco Ld (he “Company” o “ueweleo" forth purpose of providing information othe Company's shareholders rearing the proposed business combination and related wansacions involving Newol nvstment Cop I ( NewHld) (olecoeely. the Transaction
Slide 3: A Successful Journey, Driven by a Great Combination of Industrial and Management Expertise
A Successful Journey, Driven by a Great Combination of Industrial and Management Expertise Stefano Buono, Co-Founder and Chief Executive Officer = 3s Bie.
Slide 4: Policy Changes Communicated at our AGM in June 2025 Affected newcleo's Strategy and Success in the US
Policy Changes Communicated at our AGM in June 2025", Affected nevcleo’s Strategy and Success in the US Is the US policy changing? Yes, it look so, and it is very important for us * Our mul -recycling strategy could be now needed and sustained in US Our reactor technology is “unknown” in US (excludi
Slide 5: What Happened Since our AGM in June 2025?
What Happened Since our AGM in June 2025 ? Strategic Growth Institutional Engagement Capital Markets newcleo announced a strategic partnership alongside Oklo Inc. and Blykalla to develop advanced nuclear fuel fabrication capabilities and the establishment of a manufacturing infrastructure in the Uni
Slide 6: NHIC III - experienced sponsor with proven de-SPAC execution
NHIC III - experienced sponsor with proven de-SPAC execution Execution-focused sponsor partnering with newcleo to support its transition to — and long-term success in — the public markets Chief Executive Officer NHIC Ill: Role and Ongoing Partnership Kevin Chariton + CEO of NHIC I I, &1V + President
Slide 7: Transaction Summary
Slide 8: Executing Our Strategic Roadmap | Progress Since BCA
Executing Our Strategic Roadmap | Progress Since BCA Since announcing the business combination, newcleo has delivered meaningful progress across commercialization, regulatory engagement, strategic partnerships, vertical integration and fuel cycle execution — continuing to advance each pillar of its
Slide 9: What Sets newcleo Apart?
What Sets nevcleo Apart? A leading Gen IV reactor business Per OECD Nuclear Energy Agency’, we rank... among fast reactors in Eur (8 designs) #2. among European SMRs (19 designs) just behind Rolls-Royce SMR William Magwood, Director-General of the OECD Nuclear Energy Agency (OECD/NEA) and former Dir
Slide 10: Path to Commercialization: Successive Large-Scale Deployment
Path to Commercialization: Successive Large-Scale Deployment newcleo is delivering incremental hardware milestones to build technical and commercial credibility for future scaling been staffed to allow early de-risking of fae =sel Prediction Copacty as Asa result, technology and capacity gaps have b
Slide 11: Development and Qualification Investments Delivering Value
Development and Qualification Investments Delivering Value newcleo has made significant and tangible strides demonstrating progress towards physical products Materials Lab newcleo's laboratory infrastructures are a strategic pillar for the materials development roadmap, providing the technical backb
Slide 12: Strengthening our Governance with US Experienced Directors
Strengthening our Governance with US Experienced Directors Board of Directors With effect from the Listing, it is proposed that Jeffrey J Lyash, Suzy Taherian and Heinz Maeusli will be appointed as additional non-executive directors of the Company and Adrienne Kelbie will resign as a non-executive d
Slide 13: Next Steps
Next Steps «+. Of the deSPAC process Closing of the Analyst Day Transaction FA Filing aq C ar ee / A e/a /j\ es / ay /\ > Newcleo SPAC First Day of é y | Shareholder Vote Trading for NWCL nnits announced Nasdag jg, | 5 Via SPAC Deal with ... Of newcleo’s technology deployment ) . NewHold Investment
Slide 14: NHIC Closing Price Has Tracked the Sector Since Announcement
NHIC Closing Price Has Tracked the Sector Since Announcement NHIC shares currently trading ~6% above IPO price of $10.00/share ISTIC ac Shae CR AmnotascarSat IE! ase Rasctol Companies . * NHIC has traded generally flat * Volume traded has fallen off since the days surrounding announcement —acommon o
Slide 15: Thank you
Slide 16: Financial Statements FY 2025
FY 2025 Financial Statements ; General Assembly August 2026
Slide 17: FY2025 financial highlights
FY2025 financial highlights newcleo's FY2025 financial statements — four key elements Revenue-generating operations alongside the LFR/MOX program Manufacturing and installation of nuclear-grade pumps and spare parts, decommissioning and waste-storage equipment, and engineering consultancy, in additi
Slide 18: Financial Highlights FY2025
Financial Highlights FY2025 All figures in € millions | Variance vs FY2024 Revenue Other income Net loss PP&E, net €32.8m €19.3m (€140.0m) €93.4m vs €46.7m (FY24) vs €17.7m (FY24) vs (€110.2m) (FY24) vs €58.8m (Dec-24) (29.9)% +9.0% (27.1)% +58.9% Increase driven by €43m capex, mainly Wider loss ref
Slide 19: FY2025 cash bridge
FY2025 cash bridge ‘Movement in cash & cash equivalents | In € millions FY2025 movement in cash & cash equivalents (€m) 250 Cash bridge — key drivers + Operating €(119.7)m — €140m net loss, partly offset by non-cash items (D&A, share- 200 based payments) + Investing €(48.3)m — €43m capex on the Prec
Slide 20: 2026 Post-closing events
2026 Post-closing events Events after the reporting period | Statutory FY2025 & interim Q1 FY26 accounts October Capital Raise Yan 2026 @ 1: €5 40/share — €38.6m raised in October 2025 and €18.8m in January 2026 (€57.4m total) NextChem share exchange penne AP stig SA chains exchanged for newcleo Ltd
Slide 21: Consolidated Statement of Profit or Loss
Consolidated Statement of Profit or Loss In € thousands | Year ended 31 December Revenue 32,769 46,743 (13,974) 29.9% Cost of sales (24,953) (34,999) 10,046 28.7% Gross profit 7.816 11,744 (3.928) 33.4% Other income 19,347 17,746 1,601 9.0% Research and development expenses (68,544) (68,473) (10,071
Slide 22: Consolidated Statement of Financial Position
Consolidated Statement of Financial Position In € thousands | As of 31 December ASSETS LIABILITIES & EQUITY Goodwill 37,281 37,281 Provisions (NC) 4,170 3519 Intangible assets, net 43,054 46,436 (8,382) Other non-current liabilities 9,305 1 9,304 Property, plant and equipment 93,436 58,783 34,653 Le
Slide 23: Important Information for Investors and Shareholders
Important Information for Investors and Shareholders Newcleo filed the Registration Statement with the SEC, which includes a preliminary proxy statement of NewHold and a prospectus of newcleo (the “Proxy Statement/Prospectus”) in connection with the proposed business combination between NewHold and